Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
B. Dymek (Warsaw, Poland), P. Sklepkiewicz (Warsaw, Poland), M. Mlacki (Warsaw, Poland), A. Zagozdzon (Warsaw, Poland), R. Koralewski (Warsaw, Poland), M. Mazur (Warsaw, Poland), M. Paplinska-Goryca (Warsaw, Poland), P. Nejman-Gryz (Warsaw, Poland), M. Proboszcz (Warsaw, Poland), K. Gorska (Warsaw, Poland), M. Maskey-Warzechowska (Warsaw, Poland), N. Przysucha (Warsaw, Poland), R. Krenke (Warsaw, Poland), A. Golebiowski (Warsaw, Poland), P. Dobrzanski (Warsaw, Poland), K. Dzwonek (Warsaw, Poland). CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosis. 5361

Member's Comments

No comment yet.

Related content which might interest you: GED-0507 as a novel anti-fibrotic treatment option for pulmonary fibrosis Source: International Congress 2018 – Regenerative and anti-fibrotic approaches Year: 2018 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by inhibition of multiple pro-inflammatory/fibrotic key mediators Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 Evaluation of novel LOXL2-selective inhibitors in models of pulmonary fibrosis Source: International Congress 2017 – Cellular signalling pathways in pulmonary fibrosis Year: 2017 PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by regulating inflammatory cytokines in bronchoalveolar fluid Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013 The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis Source: Eur Respir Rev, 29 (157) 200269; 10.1183/16000617.0269-2020 Year: 2020 Anti-fibrotic efficacy of nintedanib on pulmonary fibrosis via suppression of fibrocyte activity Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 ELMOD2, a candidate gene for idiopathic pulmonary fibrosis, regulates antiviral responses Source: Annual Congress 2010 - Lung cell biology and immunology Year: 2010 The JAK3 inhibitor CP-690550 is a potent anti-fibrosis agent in a murine model of pulmonary fibrosis induced by bleomycin Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 A novel chronic murine model of idiopathic pulmonary fibrosis Source: International Congress 2018 – Pulmonary fibrosis: from models to patients Year: 2018 The novel oligonucleotide therapeutics PK-7010 for TGF-ß1 ameliorates bleomycin-induced pulmonary fibrosis in mice Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis Year: 2020 Effects of a neutrophil elastase inhibitor against mediators of acute exacerbation of pulmonary fibrosis: a new therapeutic strategy Source: Annual Congress 2008 - New therapeutic strategies in idiopathic pulmonary fibrosis Year: 2008 The efficacy of anti-fibrotic agents for acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Roles of α1-acid glycoprotein in therapeutic effects of imatinib in bleomycin-induced pulmonary fibrosis: benefits of macrolides Source: Annual Congress 2007 - Recent advances in the understanding of lung injury and repair Year: 2007 MUC5B genotype affects survival of patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 LSC Abstract – A human lung explant model of fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis Source: International Congress 2016 – Molecular immunology of the lung Year: 2016 PBI-4425, a novel first-in-class anti-inflammatory/anti-fibrotic compound, reduces pulmonary emphysema and cutaneous hyperplasia in tight-skin (Fbn-1) mouse Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017 Comparison of in-vivo anti-fibrotic effects of pirfenidone and nintedanib in bleomycin-induced pulmonary fibrosis model Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019